Skip to main content
Premium Trial:

Request an Annual Quote

BioMerieux's GI Panel Cleared by FDA

NEW YORK (GenomeWeb) – BioMérieux today announced that BioFire's FilmArray Gastrointestinal Panel has received 510(k) clearance for marketing by the US Food and Drug Administration.

The 22-target panel is for diagnosing infectious diarrhea and includes bacteria, viruses, and parasites in one test. According to BioMérieux, the test is the most comprehensive gastrointestinal panel to be cleared by FDA and contains several pathogens that have received FDA clearance for the first time.

BioMérieux acquired the test as part of its €357 million ($495 million) buy of BioFire Diagnostics at the start of the year. BioFire submitted its 501(k) application to FDA for the GI panel in February.

The panel runs on the FilmArray system, a closed system that integrates sample preparation, amplification, and detection, and is performed directly from stool in Cary Blair transport media. It takes two minutes to set up and about one hour to produce results, BioMérieux said.

Randy Rasmussen, CEO of BioFire Diagnostics and corporate VP of molecular biology at BioMérieux, said in a statement that the test is a "game-changer in the diagnosis of infectious diarrhea. ... The breadth of pathogens on our GI Panel provides physicians with the underlying causes of gastrointestinal infectious disease, which aids with treatment decisions for their patients."

BioFire anticipates CE-IVD marking for the panel in late spring. The firm now has three panels that have received FDA clearance, including the Respiratory Panel and the Blood Culture Identification Panel. It also has begun studies for its Meningitis-Encephalitis Panel and expects to submit the test to FDA for clearance in 2015, BioMérieux said.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.